Drugs /

tebentafusp

Back to Drugs List

Overview

NCI Definition [1]:
A fusion protein containing a modified form of human T-cell receptor (TCR) specific for the gp100 antigen and fused to an anti-CD3 single-chain antibody fragment, with potential antineoplastic activity. Upon direct intratumoral administration of tebentafusp into the melanoma lesion, the TCR moiety of this agent targets and binds to the tumor associated antigen (TAA) gp100 presented on the melanoma tumor cell; the anti-CD3 fragment moiety binds to CD3- expressing T lymphocytes, thereby selectively cross-linking tumor cells and T-lymphocytes. This may lead to the recruitment of cytotoxic T lymphocytes (CTL) to the T lymphocyte/tumor cell aggregates and result in CTL-mediated death of gp100-expressing melanoma cancer cells.

Clinical Trials

View Clinical Trials for tebentafusp

Tebentafusp has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating tebentafusp, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open).

HLA-A*02 Positive and HLA-A*02:01 Positive are the most frequent biomarker inclusion criteria for tebentafusp clinical trials.

Uveal melanoma and melanoma are the most common diseases being investigated in tebentafusp clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Tebentafusp
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating tebentafusp and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
monoclonal t-cell receptor anti-cd3 scfv fusion protein imcgp100, imcgp100, immtac-gp100
Drug Target(s) [2]:
CD3, PMEL
NCIT ID [1]:
C94208

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.